Developer docs
API playgroundTry for free, no card

Search company profiles

Evergreen Theragnostics

Full company profile

uuid0000trf

Namestring
Evergreen Theragnostics
Legal namestring
Evergreen Theragnostics Inc.
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Evergreen Theragnostics was a privately held radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) founded in 2019 and headquartered in Springfield, New Jersey. The company operated a 14,000 square foot GMP-compliant facility featuring seven commercial-scale production suites licensed for a broad portfolio of diagnostic and therapeutic isotopes, including Ac-225, At-211, Pb-212, Th-227, Cu-64, Cu-67, Ga-68, Lu-177, I-131, and others, plus a dedicated alpha emitter production center built in partnership with Tema Sinergie. Evergreen served pharmaceutical and biotechnology companies developing oncology radiopharmaceuticals, providing end-to-end services spanning radiochemistry development, analytical method development, tech transfer, early- and late-stage clinical manufacturing, commercial-scale supply, and QA/QC and logistics, with a strategic location 15 minutes from Newark International Airport supporting just-in-time delivery of short-half-life products.

The company's business model combined CDMO service fees from clients such as Precirix, Molecular Targeting Technologies (MTTI), Clovis Oncology, Clarity Pharmaceuticals, and Cellectar Biosciences with proprietary product development and licensing revenue. Evergreen's proprietary pipeline included OCTEVY (Ga-68 DOTATOC Injection), a registrational-stage PET diagnostic for somatostatin receptor-positive neuroendocrine tumors, and EVG321, a CCK2R-targeted radioligand therapy licensed from the Medical University of Innsbruck for small cell lung cancer, developed as a Lu-177 therapeutic and Ga-68 diagnostic theranostic pair. A subsidiary, Evergreen Discovery (launched 2023 near Princeton, NJ), focused on novel radiopharmaceutical drug discovery, including a peptide-discovery collaboration with Orbit Discovery. Distribution of OCTEVY was supported through a June 2023 agreement with Jubilant DraxImage for U.S. PET customers.

Over its independent life, Evergreen raised approximately $50 million across three funding rounds, including a $15M Series B (March 2023) and a $26M Series B (April 2024) led by Petrichor and LIFTT. In January 2025, Lantheus Holdings announced a definitive agreement to acquire Evergreen for $250 million upfront plus up to $752.5 million in development and sales milestone payments tied to OCTEVY and the broader pipeline, with closing expected in the second half of 2025. The acquisition positions the combined entity as a fully integrated radiopharmaceutical company spanning manufacturing, diagnostics, and therapeutics.

Short descriptiontext

Evergreen Theragnostics was a radiopharmaceutical CDMO operating a 14,000 sq ft GMP facility in Springfield, NJ, providing contract manufacturing and proprietary theranostic products (OCTEVY, EVG321) to pharmaceutical and biotech companies developing cancer radiopharmaceuticals.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSpringfield, United States
HQ citystring
Springfield
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
radiopharmaceutical CDMO services, radioligand therapy manufacturing, radiopharmaceutical contract manufacturing, theranostic radiopharmaceuticals, alpha emitter production
Industry3 codes
PRIMARYHLAIAGAF
Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYEUAKAIAC
Radiopharmaceutical Manufacturing & CDMO (Synthesis, GMP, Packaging, QA/QC)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Surgical & Medical Instruments & Apparatus3841
Product category
Radiopharmaceutical CDMO Services
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1CDMO Manufacturing Services
TypeProfessional Services
Description

Contract Development and Manufacturing Organization services for therapeutic and diagnostic radiopharmaceuticals. Services include manufacturing development, analytical method development, early-stage clinical manufacturing (Phase I/II), late-stage and commercial supply manufacturing, tech transfer, quality assurance/control, and logistics. Revenue generated from service fees across drug development lifecycle.

finsmes.com
2Product Commercialization
TypeOne Time License
Description

Commercialization of proprietary radiopharmaceutical products including OCTEVY, a PET diagnostic agent for neuroendocrine tumors. Revenue from product sales once regulatory approvals are obtained.

prnewswire.com
3Licensing and Milestone Payments
TypeLicensing Royalties
Description

Revenue from licensing proprietary technologies and pipeline products (EVG321) with potential milestone payments tied to clinical and regulatory achievements.

finsmes.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Evergreen Theragnostics is a contract development and manufacturing organization (CDMO) that provides end-to-end radiopharmaceutical manufacturing services for therapeutic and diagnostic agents, from radiochemistry development and analytical method development through early-stage clinical manufacturing to commercial-scale supply. The company also develops and commercializes proprietary theranostic products including OCTEVY (Ga-68 DOTATOC) for neuroendocrine tumor imaging and EVG321 for small cell lung cancer, leveraging a 14,000 sq ft GMP facility with seven commercial-scale production suites and dedicated alpha emitter capabilities.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 7 commercial-scale production suites for radiopharmaceutical manufacturing
+2 more records
Product overview1 text field

Evergreen Theragnostics operates as a radiopharmaceutical company with three core business units: CDMO services (contract development and manufacturing), proprietary product development/commercialization, and drug discovery (via Evergreen Discovery). The primary proprietary product is OCTEVY™ (Ga-68 DOTATOC), a registrational-stage PET diagnostic agent for neuroendocrine tumors that can function as a theranostic pair with Lantheus' PNT2003 therapeutic. The company is also advancing EVG321, a novel radioligand therapy targeting CCK2R in small cell lung cancer, available as both a 68Ga diagnostic and 177Lu therapeutic agent (theranostic pair). Evergreen Discovery focuses on first-in-class radiopharmaceutical discovery. The CDMO arm offers end-to-end manufacturing across a wide range of diagnostic and therapeutic isotopes (Ga-68, Lu-177, Cu-64, Cu-67, Ac-225, I-131, and more) from its Springfield, NJ GMP facility with seven production suites and dedicated alpha capabilities. The company was acquired by Lantheus in 2025 for up to $1 billion ($250M upfront + up to $752.5M milestones).

Product and service3 records
1CDMO Services (Contract Development and Manufacturing)
CategoryContract Manufacturing Services
Description

End-to-end contract development and manufacturing services for radiopharmaceuticals, including radiochemistry development, early- and late-stage clinical manufacturing, commercial-scale manufacturing, alpha therapy manufacturing, technology transfer, analytical method development, QA/QC, and logistics. Services span a wide range of diagnostic and therapeutic isotopes including Ga-68, Lu-177, Cu-64, Cu-67, Ac-225, I-131, and others, serving pharmaceutical and biotech companies developing radiopharmaceuticals for cancer treatment and diagnostics.

2OCTEVY™ (Ga-68 DOTATOC Injection)
CategoryRadiopharmaceutical Diagnostic Product
Description

A registrational-stage PET diagnostic agent for the localization of somatostatin receptor-positive neuroendocrine tumors in adult and pediatric patients. Uses Gallium-68 labeled DOTATOC for PET imaging, designed to function as a theranostic pair with therapeutic agents. The product is targeted for commercialization as Evergreen's first proprietary diagnostic product.

3EVG321
CategoryRadiopharmaceutical Therapeutic Product
Description

A novel radioligand therapy targeting the cholecystokinin 2 receptor (CCK2R) for small cell lung cancer. Available as a theranostic pair with both a therapeutic agent (Lutetium-177 EVG-321) and a diagnostic agent (Gallium-68 EVG-321). Licensed from Medical University of Innsbruck and in clinical development with the CCK2-VIEW Phase II trial open in the EU.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
1Medical University of Innsbruck
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-28
Description

Licensing and collaboration agreement for EVG321, a novel radioligand therapy targeting CCK2R for small cell lung cancer. The university's research groups led by Univ. Prof. Dr. Irene Virgolini and Priv. Doz. Dr. Elisabeth von Guggenberg are key innovators in the RLT field.

synapse.patsnap.com
2Jubilant DraxImage Inc.
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-06-01
Description

Distribution agreement for the preparation, sale, and distribution of OCTEVY (Ga-68 DOTATOC Injection) doses to PET customers across the United States. This partnership enables broad market access for Evergreen's diagnostic product.

insightaceanalytic.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-04-03
Description

Collaboration between Evergreen Discovery and Orbit Discovery to identify specific cell targeting peptides for novel radiopharmaceuticals. Leverages Orbit's peptide display technologies and FACS-based screening methodologies.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-03-16
Description

Development and manufacturing services agreement for Actinium-225-Labeled FAP-2286 (225Ac-FAP-2286), a targeted radiotherapeutic. Evergreen develops radiolabeling chemistry and analytical methods for potential preclinical and clinical studies at its Springfield, NJ facility.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-12-01
Description

Evergreen manufactures MTTI's EvaThera platform of radiopharmaceuticals including EBTATE (targeting neuroendocrine tumors) and EBRGD (targeting integrin expressing cancers like glioblastoma). Evergreen provides supply chain management from isotope sourcing to drug delivery at clinical trial sites.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-09-30
Description

Targeted Copper Theranostics manufacturing agreement for Cu-64 and Cu-67 based products including SAR-Bombesin (pan-cancer diagnostic/therapeutic) and SARTATE (neuroblastoma). Expanded in August 2022 to include 67Cu SAR-Bombesin for prostate cancer trials.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-08-16
Description

Commercial manufacturing and supply agreement for iopofosine I-131 (CLR-131) for clinical studies in Waldenstrom's macroglobulinemia and multiple myeloma, as well as long-term commercial supply upon approval.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-04-28
Description

Manufacturing partnership for CAM-H2, a single-domain antibody radiopharmaceutical targeting HER2-positive cancers labeled with I-131. Evergreen produces clinical trial batches for Phase I/II trial expansion to US.

Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Distributes and manufactures radiopharmaceuticals for hospitals and clinics across the US, with extensive nuclear pharmacy and manufacturing infrastructure. Comparable CDMO/distribution peer with overlapping diagnostic radiopharma services.

TypeEmerging player
Description

Developer and manufacturer of diagnostic and therapeutic radiopharmaceuticals, with in-house manufacturing for several commercial and late-stage programs. Comparable in isotope platform (Lu-177, Ga-68, I-131) and radiopharma commercialization focus.

TypeDirect peer
Description

One of the largest global radiopharmaceutical CDMOs, offering GMP manufacturing and distribution of diagnostic and therapeutic radiopharmaceuticals. Directly comparable to Evergreen as a multi-isotope CDMO serving pharma and biotech customers.

TypeDirect peer
Description

US-based radiopharmaceutical isotope production and CDMO platform focused on therapeutic and diagnostic radioisotopes including Mo-99, Cu-67, and others. Comparable as a US-focused radiopharma manufacturer and CDMO.

TypeBroad incumbent
Description

Parent company of Evergreen Theragnostics since January 2025 and a leading radiopharmaceutical company with commercial diagnostic products and a therapeutic pipeline (PNT2003). Now both acquirer and broader incumbent integrating Evergreen's CDMO platform.

TypeDirect peer
Description

Operates a large network of PET radiopharmaceutical manufacturing and distribution centers across the US and globally. Closely comparable to Evergreen's Ga-68 and other diagnostic radiopharma CDMO operations and distribution model.

TypeBroad incumbent
Description

Pharmaceutical conglomerate with significant radiopharmaceutical interests including Xofigo (Ra-223) and ongoing investments in targeted radionuclide therapy. Comparable as a large incumbent with therapeutic radiopharma manufacturing.

TypeRegional player
Description

Producer of medical radioisotopes (including Tc-99m, Ga-68, Cu-64) and related CDMO services for radiopharmaceutical developers. Comparable to Evergreen's isotope-focused manufacturing and supply capabilities.

TypeOthers
Description

Clinical-stage radiopharmaceutical developer (Cu-64/Cu-67 SAR-Bombesin, SARTATE) that has used Evergreen as its US CDMO. Adjacent peer representing the biotech customer category Evergreen serves.

TypeBroad incumbent
Description

Global diagnostic imaging company with radiopharmaceutical manufacturing capabilities and a broad contrast/radiopharma portfolio. Overlaps with Evergreen's diagnostic imaging and CDMO offerings as a larger diversified incumbent.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Evergreen Theragnostics

Radiopharmaceutical CDMO Servicesevergreentgn.com

Evergreen Theragnostics was a radiopharmaceutical CDMO operating a 14,000 sq ft GMP facility in Springfield, NJ, providing contract manufacturing and proprietary theranostic products (OCTEVY, EVG321) to pharmaceutical and biotech companies developing cancer radiopharmaceuticals.

What Evergreen Theragnostics does

Evergreen Theragnostics was a privately held radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) founded in 2019 and headquartered in Springfield, New Jersey. The company operated a 14,000 square foot GMP-compliant facility featuring seven commercial-scale production suites licensed for a broad portfolio of diagnostic and therapeutic isotopes, including Ac-225, At-211, Pb-212, Th-227, Cu-64, Cu-67, Ga-68, Lu-177, I-131, and others, plus a dedicated alpha emitter production center built in partnership with Tema Sinergie. Evergreen served pharmaceutical and biotechnology companies developing oncology radiopharmaceuticals, providing end-to-end services spanning radiochemistry development, analytical method development, tech transfer, early- and late-stage clinical manufacturing, commercial-scale supply, and QA/QC and logistics, with a strategic location 15 minutes from Newark International Airport supporting just-in-time delivery of short-half-life products.

The company's business model combined CDMO service fees from clients such as Precirix, Molecular Targeting Technologies (MTTI), Clovis Oncology, Clarity Pharmaceuticals, and Cellectar Biosciences with proprietary product development and licensing revenue. Evergreen's proprietary pipeline included OCTEVY (Ga-68 DOTATOC Injection), a registrational-stage PET diagnostic for somatostatin receptor-positive neuroendocrine tumors, and EVG321, a CCK2R-targeted radioligand therapy licensed from the Medical University of Innsbruck for small cell lung cancer, developed as a Lu-177 therapeutic and Ga-68 diagnostic theranostic pair. A subsidiary, Evergreen Discovery (launched 2023 near Princeton, NJ), focused on novel radiopharmaceutical drug discovery, including a peptide-discovery collaboration with Orbit Discovery. Distribution of OCTEVY was supported through a June 2023 agreement with Jubilant DraxImage for U.S. PET customers.

Over its independent life, Evergreen raised approximately $50 million across three funding rounds, including a $15M Series B (March 2023) and a $26M Series B (April 2024) led by Petrichor and LIFTT. In January 2025, Lantheus Holdings announced a definitive agreement to acquire Evergreen for $250 million upfront plus up to $752.5 million in development and sales milestone payments tied to OCTEVY and the broader pipeline, with closing expected in the second half of 2025. The acquisition positions the combined entity as a fully integrated radiopharmaceutical company spanning manufacturing, diagnostics, and therapeutics.

Evergreen Theragnostics firmographics

Firmographics
Name
Evergreen Theragnostics
Legal name
Evergreen Theragnostics Inc.
Website
https://evergreentgn.com
Company type
Private
Founded year
2019
Operating status
Acquired
Headcount range
51–100 employees
Short description
Evergreen Theragnostics was a radiopharmaceutical CDMO operating a 14,000 sq ft GMP facility in Springfield, NJ, providing contract manufacturing and proprietary theranostic products (OCTEVY, EVG321) to pharmaceutical and biotech companies developing cancer radiopharmaceuticals.
Ownership category
akta.pro rank

Evergreen Theragnostics industry classification

Industry
Product category
Radiopharmaceutical CDMO Services
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAIAGAF
Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYEUAKAIAC
Radiopharmaceutical Manufacturing & CDMO (Synthesis, GMP, Packaging, QA/QC)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Radiopharmaceutical CDMO services
  • Radioligand therapy manufacturing
  • Radiopharmaceutical contract manufacturing
  • Theranostic radiopharmaceuticals
  • Alpha emitter production

Where Evergreen Theragnostics is headquartered

Location

Headquarters

HQ city
Springfield
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Evergreen Theragnostics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

  1. CDMO Manufacturing Services: Contract Development and Manufacturing Organization services for therapeutic and diagnostic radiopharmaceuticals. Services include manufacturing development, analytical method development, early-stage clinical manufacturing (Phase I/II), late-stage and commercial supply manufacturing, tech transfer, quality assurance/control, and logistics. Revenue generated from service fees across drug development lifecycle.
  2. Product Commercialization: Commercialization of proprietary radiopharmaceutical products including OCTEVY, a PET diagnostic agent for neuroendocrine tumors. Revenue from product sales once regulatory approvals are obtained.
  3. Licensing and Milestone Payments: Revenue from licensing proprietary technologies and pipeline products (EVG321) with potential milestone payments tied to clinical and regulatory achievements.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Evergreen Theragnostics product offering

Product offering

Core offering

Evergreen Theragnostics is a contract development and manufacturing organization (CDMO) that provides end-to-end radiopharmaceutical manufacturing services for therapeutic and diagnostic agents, from radiochemistry development and analytical method development through early-stage clinical manufacturing to commercial-scale supply. The company also develops and commercializes proprietary theranostic products including OCTEVY (Ga-68 DOTATOC) for neuroendocrine tumor imaging and EVG321 for small cell lung cancer, leveraging a 14,000 sq ft GMP facility with seven commercial-scale production suites and dedicated alpha emitter capabilities.

Product overview

Evergreen Theragnostics operates as a radiopharmaceutical company with three core business units: CDMO services (contract development and manufacturing), proprietary product development/commercialization, and drug discovery (via Evergreen Discovery). The primary proprietary product is OCTEVY™ (Ga-68 DOTATOC), a registrational-stage PET diagnostic agent for neuroendocrine tumors that can function as a theranostic pair with Lantheus' PNT2003 therapeutic. The company is also advancing EVG321, a novel radioligand therapy targeting CCK2R in small cell lung cancer, available as both a 68Ga diagnostic and 177Lu therapeutic agent (theranostic pair). Evergreen Discovery focuses on first-in-class radiopharmaceutical discovery. The CDMO arm offers end-to-end manufacturing across a wide range of diagnostic and therapeutic isotopes (Ga-68, Lu-177, Cu-64, Cu-67, Ac-225, I-131, and more) from its Springfield, NJ GMP facility with seven production suites and dedicated alpha capabilities. The company was acquired by Lantheus in 2025 for up to $1 billion ($250M upfront + up to $752.5M milestones).

Differentiator

Problem solved

Functional benefit

Products and services

  • CDMO Services (Contract Development and Manufacturing) End-to-end contract development and manufacturing services for radiopharmaceuticals, including radiochemistry development, early- and late-stage clinical manufacturing, commercial-scale manufacturing, alpha therapy manufacturing, technology transfer, analytical method development, QA/QC, and logistics. Services span a wide range of diagnostic and therapeutic isotopes including Ga-68, Lu-177, Cu-64, Cu-67, Ac-225, I-131, and others, serving pharmaceutical and biotech companies developing radiopharmaceuticals for cancer treatment and diagnostics.
  • OCTEVY™ (Ga-68 DOTATOC Injection) A registrational-stage PET diagnostic agent for the localization of somatostatin receptor-positive neuroendocrine tumors in adult and pediatric patients. Uses Gallium-68 labeled DOTATOC for PET imaging, designed to function as a theranostic pair with therapeutic agents. The product is targeted for commercialization as Evergreen's first proprietary diagnostic product.
  • EVG321 A novel radioligand therapy targeting the cholecystokinin 2 receptor (CCK2R) for small cell lung cancer. Available as a theranostic pair with both a therapeutic agent (Lutetium-177 EVG-321) and a diagnostic agent (Gallium-68 EVG-321). Licensed from Medical University of Innsbruck and in clinical development with the CCK2-VIEW Phase II trial open in the EU.

Quantifiable outcome

  • 7 commercial-scale production suites for radiopharmaceutical manufacturing
  • +2 more outcomes

Companies that use Evergreen Theragnostics

Customer profile

Named customers7 records

Segments3 records

Ideal customer profiles1 record

Evergreen Theragnostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Evergreen Theragnostics partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core.

  • Medical University of InnsbruckcoreStrategic or Co-development Partner · 28 May 2024Licensing and collaboration agreement for EVG321, a novel radioligand therapy targeting CCK2R for small cell lung cancer. The university's research groups led by Univ. Prof. Dr. Irene Virgolini and Priv. Doz. Dr. Elisabeth von Guggenberg are key innovators in the RLT field.
  • Jubilant DraxImage Inc.coreChannel Partner/ Reseller/ Distributor · 1 June 2023Distribution agreement for the preparation, sale, and distribution of OCTEVY (Ga-68 DOTATOC Injection) doses to PET customers across the United States. This partnership enables broad market access for Evergreen's diagnostic product.
  • Orbit DiscoverycoreStrategic or Co-development Partner · 3 April 2023Collaboration between Evergreen Discovery and Orbit Discovery to identify specific cell targeting peptides for novel radiopharmaceuticals. Leverages Orbit's peptide display technologies and FACS-based screening methodologies.
  • Clovis OncologycoreStrategic or Co-development Partner · 16 March 2022Development and manufacturing services agreement for Actinium-225-Labeled FAP-2286 (225Ac-FAP-2286), a targeted radiotherapeutic. Evergreen develops radiolabeling chemistry and analytical methods for potential preclinical and clinical studies at its Springfield, NJ facility.
  • Molecular Targeting Technologies (MTTI)coreStrategic or Co-development Partner · 1 December 2021Evergreen manufactures MTTI's EvaThera platform of radiopharmaceuticals including EBTATE (targeting neuroendocrine tumors) and EBRGD (targeting integrin expressing cancers like glioblastoma). Evergreen provides supply chain management from isotope sourcing to drug delivery at clinical trial sites.
  • Clarity PharmaceuticalscoreStrategic or Co-development Partner · 30 September 2021Targeted Copper Theranostics manufacturing agreement for Cu-64 and Cu-67 based products including SAR-Bombesin (pan-cancer diagnostic/therapeutic) and SARTATE (neuroblastoma). Expanded in August 2022 to include 67Cu SAR-Bombesin for prostate cancer trials.
  • Cellectar BiosciencescoreStrategic or Co-development Partner · 16 August 2021Commercial manufacturing and supply agreement for iopofosine I-131 (CLR-131) for clinical studies in Waldenstrom's macroglobulinemia and multiple myeloma, as well as long-term commercial supply upon approval.
  • PrecirixcoreStrategic or Co-development Partner · 28 April 2021Manufacturing partnership for CAM-H2, a single-domain antibody radiopharmaceutical targeting HER2-positive cancers labeled with I-131. Evergreen produces clinical trial batches for Phase I/II trial expansion to US.

Scale indicators8 records

Recent moves10 records

Expansion highlights6 records

Evergreen Theragnostics competitors and assessment

Company assessment

Direct peers

  • Cardinal Health Nuclear & Precision Health Solutions: Distributes and manufactures radiopharmaceuticals for hospitals and clinics across the US, with extensive nuclear pharmacy and manufacturing infrastructure. Comparable CDMO/distribution peer with overlapping diagnostic radiopharma services.
  • Curium: One of the largest global radiopharmaceutical CDMOs, offering GMP manufacturing and distribution of diagnostic and therapeutic radiopharmaceuticals. Directly comparable to Evergreen as a multi-isotope CDMO serving pharma and biotech customers.
  • NorthStar Medical Radioisotopes: US-based radiopharmaceutical isotope production and CDMO platform focused on therapeutic and diagnostic radioisotopes including Mo-99, Cu-67, and others. Comparable as a US-focused radiopharma manufacturer and CDMO.
  • PETNET Solutions (Siemens Healthineers): Operates a large network of PET radiopharmaceutical manufacturing and distribution centers across the US and globally. Closely comparable to Evergreen's Ga-68 and other diagnostic radiopharma CDMO operations and distribution model.

Emerging players

  • Telix Pharmaceuticals: Developer and manufacturer of diagnostic and therapeutic radiopharmaceuticals, with in-house manufacturing for several commercial and late-stage programs. Comparable in isotope platform (Lu-177, Ga-68, I-131) and radiopharma commercialization focus.

Broad incumbents

  • Lantheus Holdings: Parent company of Evergreen Theragnostics since January 2025 and a leading radiopharmaceutical company with commercial diagnostic products and a therapeutic pipeline (PNT2003). Now both acquirer and broader incumbent integrating Evergreen's CDMO platform.
  • Bayer (Radiology / Algeta heritage): Pharmaceutical conglomerate with significant radiopharmaceutical interests including Xofigo (Ra-223) and ongoing investments in targeted radionuclide therapy. Comparable as a large incumbent with therapeutic radiopharma manufacturing.
  • Bracco Imaging: Global diagnostic imaging company with radiopharmaceutical manufacturing capabilities and a broad contrast/radiopharma portfolio. Overlaps with Evergreen's diagnostic imaging and CDMO offerings as a larger diversified incumbent.

Regional players

  • ARTMS / BWXT Medical: Producer of medical radioisotopes (including Tc-99m, Ga-68, Cu-64) and related CDMO services for radiopharmaceutical developers. Comparable to Evergreen's isotope-focused manufacturing and supply capabilities.

Others

  • Clarity Pharmaceuticals: Clinical-stage radiopharmaceutical developer (Cu-64/Cu-67 SAR-Bombesin, SARTATE) that has used Evergreen as its US CDMO. Adjacent peer representing the biotech customer category Evergreen serves.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Evergreen Theragnostics social profiles

Digital presence

Evergreen Theragnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Evergreen Theragnostics leadership team

Management profile

Number of profiles

Profiles4 records

Evergreen Theragnostics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Evergreen Theragnostics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Evergreen Theragnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Evergreen Theragnostics

What does Evergreen Theragnostics do?

Evergreen Theragnostics is a contract development and manufacturing organization (CDMO) that provides end-to-end radiopharmaceutical manufacturing services for therapeutic and diagnostic agents, from radiochemistry development and analytical method development through early-stage clinical manufacturing to commercial-scale supply. The company also develops and commercializes proprietary theranostic products including OCTEVY (Ga-68 DOTATOC) for neuroendocrine tumor imaging and EVG321 for small cell lung cancer, leveraging a 14,000 sq ft GMP facility with seven commercial-scale production suites and dedicated alpha emitter capabilities.

Is Evergreen Theragnostics a public or private company?

Evergreen Theragnostics is a private company. It is classified as corporate owned and is currently acquired.

When was Evergreen Theragnostics founded?

Evergreen Theragnostics was founded in 2019. It employs 51 to 100 people.

Where is Evergreen Theragnostics based?

Evergreen Theragnostics is headquartered in Springfield, United States, in the North America region.

How does Evergreen Theragnostics make money?

Three revenue lines are on record. CDMO Manufacturing Services are the primary driver. The others are product Commercialization and licensing and Milestone Payments.

Who are Evergreen Theragnostics's main competitors?

Direct peers on record are Cardinal Health Nuclear & Precision Health Solutions, Curium, NorthStar Medical Radioisotopes and PETNET Solutions (Siemens Healthineers). Telix Pharmaceuticals is listed as an emerging player. Broad incumbents are Lantheus Holdings, Bayer (Radiology / Algeta heritage) and Bracco Imaging. ARTMS / BWXT Medical is listed as a regional player. Clarity Pharmaceuticals is listed as an others.

Does Evergreen Theragnostics have an API?

No public API is recorded for Evergreen Theragnostics.

What industry is Evergreen Theragnostics in?

Evergreen Theragnostics's product category is Radiopharmaceutical CDMO Services. Its primary akta.pro industry code is HLAIAGAF, Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish), with a secondary code of EUAKAIAC, Radiopharmaceutical Manufacturing & CDMO (Synthesis, GMP, Packaging, QA/QC). Its NAICS code is 3254 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireWhy the Radiopharmaceutical CDMO Market is a Smart Investment: USD 8.50 Bn by 2035The global radiopharmaceutical CDMO market is projected to grow from USD 3.24 billion in 2025 to USD 8.50 billion by 2035, representing a compound annual growth rate of 10.12%, driven by rising nuclear medicine adoption, increasing outsourcing trends, and growing demand for targeted cancer therapies. North America currently leads the market with approximately 49% revenue share, while Asia-Pacific is expected to be the fastest-growing region through 2035. The industry is experiencing significant consolidation, with companies like Lantheus acquiring Evergreen Theragnostics for up to $1 billion, PharmaLogic acquiring a majority stake in Norway-based Agilera Pharma, and SK Pharmteco taking control of the Center for Breakthrough Medicines to expand multi-modality and radiopharmaceutical manufacturing capabilities.Precedence ResearchRadiopharmaceutical CDMO Market Report & Future TrendsThe global radiopharmaceutical CDMO market reached USD 3.24 billion in 2025 and is projected to grow to USD 8.50 billion by 2035 at a CAGR of 10.12%, driven by rising outsourcing trends, increasing cancer burden, and growing demand for theranostics and precision medicine. North America holds the dominant market share while Asia Pacific is expected to grow at the fastest rate during the forecast period. In January 2025, Lantheus announced the acquisition of Evergreen Theragnostics for USD 250 million upfront with potential additional milestone payments of up to $752.5 million.Precedence ResearchRadiopharmaceutical CDMO Market Size to Hit USD 8.50 Billion by 2035The global radiopharmaceutical CDMO market was valued at USD 3.24 billion in 2025 and is projected to reach USD 8.50 billion by 2035, growing at a CAGR of 10.12%, driven by rising nuclear medicine demand, oncology-focused innovation, and increased outsourcing of radioactive drug development and manufacturing. North America led the market with a 49% share in 2025, while the Asia Pacific region is expected to grow at the fastest rate through 2035, supported by government investments in domestic isotope production and expanding clinical trial activity. Recent developments include Lantheus's acquisition of Evergreen Theragnostics for up to $1 billion and Nucleus RadioPharma's launch of a new theranostic infusion system, reflecting active consolidation and innovation in the sector.GlobeNewswireLantheus Completes Acquisition of Evergreen TheragnosticsLantheus completed its acquisition of Evergreen Theragnostics, a clinical-stage radiopharmaceutical company. The deal includes OCTEVY, a registrational-stage PET diagnostic for neuroendocrine tumors, and Evergreen's CDMO manufacturing infrastructure. The acquisition expands Lantheus's radiopharmaceutical capabilities across development, manufacturing, and commercialization.GlobeNewswireLantheus Completes Acquisition of Evergreen TheragnosticsLantheus completed its acquisition of Evergreen Theragnostics, a clinical-stage radiopharmaceutical company. The deal includes OCTEVY, a PET diagnostic for neuroendocrine tumors, and Evergreen's CDMO manufacturing infrastructure. Lantheus aims to integrate these capabilities to expand its radiopharmaceutical value chain.GlobeNewswireLantheus Reports Fourth Quarter and Full Year 2024 Financial PerformanceLantheus reported Q4 2024 worldwide revenue of $391.1 million and full-year revenue of $1.53 billion, with PYLARIFY sales of $266.0 million. The company issued FY2025 revenue guidance of $1.545–1.610 billion and adjusted EPS of $7.00–7.20. It also announced planned acquisitions of Life Molecular and Evergreen Theragnostics.BenzingaLantheus To Buy Evergreen Theragnostics For Over $1 Billion To Bolster Its Cancer Radiopharmaceutical PorLantheus Holdings, Inc. agreed to acquire Evergreen Theragnostics, Inc. in an all-cash deal worth over $1 billion, consisting of a $250 million upfront payment and up to $752.5 million in potential milestone payments. Evergreen is a clinical-stage radiopharmaceutical company providing CDMO services, drug discovery, and proprietary product commercialization, with the transaction expected to close in the second half of 2025. The acquisition adds OCTEVY, a registrational-stage PET diagnostic agent for neuroendocrine tumors, and several theranostic pairs to Lantheus' pipeline, complementing its existing therapeutic candidate PNT2003 and solidifying its position as a fully integrated radiopharmaceutical company.ContractpharmaLantheus Holdings to Acquire Evergreen TheragnosticsLantheus Holdings Inc., a radiopharmaceutical-focused company, has agreed to acquire Evergreen Theragnostics Inc. in an all-cash transaction valued at up to $1 billion, with $250 million paid upfront and potential additional milestone payments of up to $752.5 million. The acquisition aims to provide Lantheus with scalable manufacturing capabilities and expand its oncology diagnostic pipeline through products such as OCTEVY, a registrational-stage PET diagnostic agent for neuroendocrine tumors. The transaction is expected to close in the second half of 2025, subject to regulatory approvals and customary closing conditions.Business Wire BlogOrbit Discovery and Evergreen Theragnostics Expand Research Collaboration to Advance Targeted Therapeutics DevelopmentOrbit Discovery and Evergreen Theragnostics extended their research collaboration to identify novel peptides for radiopharmaceutical delivery, building on a 2023 agreement. The partnership will use Orbit's screening platform and Evergreen's radiopharmaceutical expertise to accelerate clinical applications. Orbit Discovery will attend the Biotech Showcase in San Francisco and BIO-Europe in Milan in 2025.PatsnapEvergreen Theragnostics licenses EVG321, starts clinical trials for radioligand therapy in small cell lung cancerEvergreen Theragnostics has entered a licensing and collaboration agreement with Innsbruck Medical University to advance the clinical development of EVG321, a radioligand therapy targeting the cholecystokinin 2 receptor for small cell lung cancer treatment. The company plans to initiate clinical trials for both therapeutic and diagnostic applications using Lutetium-177 and Gallium-68 labeled EVG321 in the coming months. This partnership leverages the university's research expertise in radiopharmaceuticals to develop innovative cancer treatments targeting CCK2R, which is highly expressed in small cell lung cancer.